Vector pLNCX2 Containing HLA-B*2703 Allele

Catalog No. NR-2801

For research use only. Not for human use.

Contributor:
Ellis L. Reinherz, M.D., Professor of Medicine, Dana-Farber Cancer Insititute, Boston, Massachusetts

Manufacturer:
NIH Biodefense and Emerging Infections Research Resources Repository, NIAID, NIH

Product Description:
The HLA-B*2703 allele from a human Major Histocompatability Complex (MHC) Class I human leukocyte antigen (HLA)-homozygous human B-lymphoblastoid cell line (B-LCL) was amplified by PCR, gel purified and cloned into the Clontech Laboratories vector, pLNCX2 by the International Histocompatability Working Group (IHWG). The plasmid was produced in *Escherichia coli* DH5α™-T1^R cells (Invitrogen™) and extracted using a QIAGEN® EndoFree® Plasmid Maxi Kit.

Allele:[1] HLA-B*2703
Vector: pLNCX2
Insert Size: 1.17 kb
Selection: Ampicillin (Prokaryotic)/G418 (Eukaryotic)
IHWG B-LCL: 9376
ImMunoGeneTics: HLA00222
GenBank: M54883

NR-2801 has been qualified for use in bacterial transformations.

Material Provided:
Each vial contains 20 to 50 ng of plasmid DNA in TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 7.0). The concentration is shown on the Certificate of Analysis. The vial should be centrifuged prior to opening.

Packaging/Storage:
NR-2801 was packaged aseptically in screw-capped plastic cryovials. The product is provided frozen on dry ice and should be stored at -20°C or colder immediately upon arrival. Freeze-thaw cycles should be minimized.

Citation:
Acknowledgment for publications should read "The following reagent was obtained through the NIH Biodefense and Emerging Infections Research Resources Repository, NIAID, NIH: Vector pLNCX2 Containing HLA-B*2703 Allele, NR-2801."

Biosafety Level: 1
Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 5th ed. Washington, DC: U.S. Government Printing Office, 2007; see www.cdc.gov/od/ohs/biosfty/bmbl5/bmbl5toc.htm.

Disclaimers:
You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government make any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:
This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

References:
1. Choo, S. Y., et al. "Molecular Analysis of the Variant Alloantigen HLA-B27d (HLA-B*2703) Identifies a Unique Single Amino Acid Substitution." Hum. Immunol. 21 (1988): 209-219. PubMed: 3286582.
2. Shiina, T., et al. "Molecular Dynamics of MHC Genesis Unraveled by Sequence Analysis of the 1,796,938-bp HLA Class I Region." Proc. Natl. Acad. Sci. U. S. A. 96 (1999): 13282-13287. PubMed: 10557312.
3. Stewart, C. A., et al. "Complete MHC Haplotype Sequencing for Common Disease Gene Mapping." Genome Res. 14 (2004): 1176-1187. PubMed: 15140828.

Support Provided by NIAID

Biodefense and Emerging Infections Research Resources Repository
www.beiresources.org
E-mail: contact@beiresources.org
Tel: 800-359-7370
Fax: 703-365-2898